• 340B Insider – December 2018

    Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more.   340B INDUSTRY NEWS Read below for recent news from 340B Health. THE U.S. HOUSE PASSES BILL TO KEEP DRUG COMPANIES FROM OVERCHARGING MEDICAID The bipartisan bill, from… Read more »

  • Clinical Insights: November 7, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with… Read more »

  • Schedule Your 340B Demos Now!

    The 2018 340B Coalition Summer Conference is just around the corner. July 9-11, we will be in Washington, D.C. as a Pinnacle Leader Sponsor for the conference, ready to connect with you and gain insight into the latest news and trends concerning the 340B Drug Discount Program. If you are attending, be sure to schedule… Read more »

  • Clinical Insights: June 13, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FulphilaTM (pegfilgrastim-jmdb) – New Biosimilar Drug Approval – June 4, 2018 – The U.S. Food and Drug Administration approved FulphilaTM (pegfilgrastim-jmdb) as the first biosimilar to Neulasta®(pegfilgrastim) to… Read more »

  • Clinical Insights: May 1, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval JynarqueTM (tolvaptan) – April 24, 2018 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that the U.S. Food and Drug Administration (FDA) has approved JynarqueTM (tolvaptan) as… Read more »

  • Connect with Us at the CPS Annual Meeting & Vendor Expo

    May 2-4, Vice President – Implementations and Sales Support Ryen Brumbeloe and Sales Manager ­– Midwest Region Todd Hudnall will attend and exhibit at the Comprehensive Pharmacy Systems/Pharmacy Systems, Inc. (CPS) Annual Meeting & Vendor Expo in Indianapolis, IN. There, over 450 pharmacy decision makers will connect and gain insight into the latest industry news.… Read more »

  • Integrated Solutions to Maintain Program Compliance

    There are many challenges organizations face when maintaining a compliant 340B Drug Pricing Program. At RxStrategies, we specialize in delivering integrated solutions to assist implementation and compliance.   Split Billing Provides end-to-end 340B program management and addresses its complexity by reviewing all prescription activity to flag eligible 340B dispenses.   CompliancePlus Streamlines workflow, quickly indemnifies… Read more »

  • Clinical Insights: February 5, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval FirvanqTM (vancomycin hydrochloride) – January 29, 2018 – CutisPharma announced that the U.S. Food and Drug Administration (FDA) has approved Firvanq™ (vancomycin hydrochloride) for oral solution, for the… Read more »